Innovative clinical trials that enhance the understanding of cardiovascular disease and improve the care of patients.

 

Since its inception in 1984, the TIMI Study Group has been an Academic Research Organization dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease and its risk factors. We have led a wide array of trials, from phase I to phase IV, enrolling from less than 30 to more than 26,000 subjects, and with both industry and NIH support. Trials have been conducted in over 50 countries and at more than 5000 separate sites.

We investigate a broad array of therapeutic interventions in individuals across the spectrum of cardiovascular disease, ranging from prevention in those with risk factors, to emergent interventions in those with acute manifestations of disease. In addition, we have used our large database of clinical findings, biomarkers, and genotypes to enhance the understanding of cardiovascular disease and its risk factors.

By leading large-scale, international, randomized controlled trials of novel therapeutics and performing sophisticated analyses, we have been privileged to help shape the very practice of cardiovascular medicine for over a quarter of a century.

LEARN MORE

Academic Trial Leadership

TIMI Study Group investigators provide leadership for clinical trial design, execution, and analysis

Global Trial Operations

Global Trial Management, Biostatistics, Clinical Events Committee, Safety Desk, Medical Hotline

Core Labs

Biomarkers, Proteomics, Metabolomics, Genomics, ECG

Publications

Practice-changing contributions to the medical literature

Current and Recent Trials

Recent News and Publications

8/28/2017 -  Slide deck and paper for achieved very low LDL-C in FOURIER now available 

8/28/201 - New Publication: Ference B et al., Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. 2017 Lancet.

3/17/2017 - FOURIER primary results slide deck and NEJM paper now available

3/12/2017 - TIMI Presentation Schedule See what TIMI Investigators are up to at ACC.17

3/14/2017 - New Publication: Koren MJ, Sabatine MS, Giugliano RP et al., Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. 2017 JAMA Cardiol.

 More News